Physician profile
William C Adcox
NPI 1124086350
$11,004.37
in general payments reported to CMS, 2019-2025
51 companies · $1,400 in 2025
The $1,400 reported for 2025 was more than what 91% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,311 · 2020: $1,717 · 2021: $3,326 · 2022: $1,702 · 2023: $820 · 2024: $729 · 2025: $1,400.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,949.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,948.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceuticals, INC. | $1,410.20 | 2020-2021 | |
| Novo Nordisk INC | $1,386.94 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $1,075.36 | 2020-2025 | Vraylar, Ubrelvy, Qulipta |
| Astrazeneca Pharmaceuticals LP | $754.09 | 2019-2025 | Airsupra, Farxiga |
| Lilly USA, LLC | $725.48 | 2019-2025 | Mounjaro, Zepbound, Trulicity |
| Otsuka America Pharmaceutical, INC. | $713.72 | 2019-2025 | Rexulti |
| Supernus Pharmaceuticals, INC. | $553.81 | 2021-2022 | |
| Pfizer INC. | $450.28 | 2020-2025 | |
| Sanofi-Aventis U.S. LLC | $388.24 | 2019-2025 | |
| Amgen INC. | $357.11 | 2019-2025 | Otezla, Repatha, Otezla |
| Boehringer Ingelheim Pharmaceuticals, INC. | $356.30 | 2019-2023 | Tradjenta |
| Aytu Biopharma, INC. | $227.75 | 2019-2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $220.63 | 2019-2025 | Xifaxan |
| Allergan, INC. | $180.48 | 2019-2020 | |
| Astellas Pharma US INC | $175.55 | 2019-2024 | Veozah |
Show all 51 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Adcox listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.